Nov 6 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
IONIS ANNOUNCES PIVOTAL PHASE 3 TRIAL DESIGN FOR ION582 IN ANGELMAN SYNDROME
IONIS PHARMACEUTICALS INC - POSITIVE END OF PHASE 2 DISCUSSION WITH FDA
IONIS PHARMACEUTICALS INC - BAYLEY-4 EXPRESSIVE COMMUNICATION SELECTED AS PHASE 3 PRIMARY ENDPOINT
IONIS PHARMACEUTICALS INC - ION582 PHASE 3 STUDY INITIATION PLANNED FOR H1 2025
Source text: ID:nPnyRJJNa
Further company coverage: IONS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.